Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label Clinical Trial to Evaluate the Safety and Efficacy of CT103A Cells for the Treatment of Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System

Next Previous
X
Search
Trial Profile

An Open Label Clinical Trial to Evaluate the Safety and Efficacy of CT103A Cells for the Treatment of Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System

Status: Recruiting
Phase of Trial: Phase 0

Latest Information Update: 15 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Equecabtagene autoleucel (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Autoimmune diseases of the nervous system; Encephalitis; Multiple sclerosis; Myasthenia gravis; Neuromyelitis optica; POEMS syndrome
  • Focus Adverse reactions
  • Acronyms CARTinNS

    • Most Recent Events

    • 01 Jul 2024 According to an IASO BioMed media release, results form this trial were presented at the 2024 European Academy of Neurology (EAN) Annual Meeting.
    • 01 Jul 2024 Results presented in the IASO BioMed Media Release.
    • 04 May 2024 Planned number of patients changed from 18 to 36.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top